Cadila Healthcare says FDA inspection at Ahmedabad facility had no observations

FDA
Recent FDA inspection finds no observations of of Indian drugmaker Cadila Healthcare's topical manufacturing facility at Changodar, Ahmedabad. (FDA)

Indian drugmaker Cadila Healthcare said a recent FDA inspection of its topical manufacturing facility at Changodar, Ahmedabad, resulted in no observations from the regulatory agency.

The inspection was conducted from March 22 through Wednesday. Of the 10 ANDA approvals the company has received from the FDA between 2016 and 2017, one was its first topical product approval for the formulations plant located in Ahmedabad. 

In late 2016, the company’s Moraiya plant, which is a formulation site, was one of two Cadila facilities in Gujarat to get warning letters the same month.

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

In those warning letters from the FDA, inspectors said they had serious concerns about Cadila's production of warfarin products following inspections in 2014. According to the agency, at least 5 batches fell short of expectations, but the drugmaker never uncovered the root cause so that it could be fixed.

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.